Sompraz%252520hp

# Sompraz HP ## Overview Sompraz HP is a prescription "Helicobacter pylori kit" (co-packaging) designed for the eradication of *H. pylori*. It typically contains a combination of **Esomeprazole** (a Proton Pump Inhibitor), **Amoxicillin** (a penicillin antibiotic), and **Clarithromycin** (a macrolide antibiotic). ## Primary Indications Treatment of *Helicobacter pylori* infection in patients with duodenal ulcer disease or chronic gastritis to reduce the risk of ulcer recurrence. ## Adult Dosing Standard therapy typically follows a twice-daily regimen for 7 to 14 days: * **Esomeprazole:** 40 mg twice daily. * **Amoxicillin:** 1000 mg twice daily. * **Clarithromycin:** 500 mg twice daily. * *Note: Refer to the specific manufacturer package insert (e.g., Sompraz HP kit packaging) as exact co-packaging may vary by territory.* ## Pediatric Dosing Not recommended for pediatric use. Efficacy and safety have not been established in the pediatric population. ## Dose Adjustments * **Renal Impairment:** Dose adjustments for Amoxicillin or Clarithromycin may be necessary if CrCl < 30 mL/min. Consult local prescribing information for specific renal dosing. * **Hepatic Impairment:** Use caution with Clarithromycin and Esomeprazole in patients with hepatic dysfunction; dosage reductions or avoidance may be required for severe cases. ## Contraindications * Known hypersensitivity to Esomeprazole, Amoxicillin, Clarithromycin, or any macrolide antibiotic. * Concomitant use with drugs known to interact with Clarithromycin (e.g., pimozide, ergot alkaloids, terfenadine, or astemizole). * History of cholestatic jaundice or hepatic dysfunction associated with prior use of macrolides. ## Adverse Effects * **Common:** Diarrhea, dysgeusia (metallic taste), nausea, abdominal pain, headache, and dizziness. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity/anaphylaxis, QT prolongation (due to Clarithromycin), and drug-induced hepatitis. ## Key Drug Interactions * **Strong CYP3A4 inhibitors/substrates:** Clarithromycin significantly inhibits CYP3A4, increasing serum levels of drugs like statins, warfarin, and benzodiazepines. * **Gastric pH-dependent drugs:** Esomeprazole may decrease absorption of atazanavir, ketoconazole, and iron salts. * **QT Prolonging Agents:** Risk of additive QT prolongation when Clarithromycin is co-administered with other arrhythmogenic agents. ## Monitoring * Monitor for signs of hypersensitivity reactions. * Monitor for persistent or severe diarrhea (signs of CDAD). * Evaluate patient for symptom resolution and eradication success (typically via urea breath test 4 weeks after antibiotic completion). ## Clinical Pearls * **Adherence is critical:** Completing the full course is essential to prevent antibiotic resistance. * **Taking the medication:** Esomeprazole should generally be taken at least 60 minutes before a meal to maximize acid suppression. * **Resistance:** *H. pylori* resistance to Clarithromycin is increasing globally; if eradication fails, a second-line regimen (e.g., bismuth-based quadruple therapy) should be selected. *** *Disclaimer: This information is for educational purposes only. Drug kits, formulations, and institutional protocols vary by region. Always verify specific dosing, clinical guidelines, and contraindications against the current manufacturer's prescribing information and your local electronic health record/formulary before prescribing or administration.*